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Summary Matrix metalloproteinases (MMPs) are zinc dependent endopeptidases implicated in cancer invasion and metastasis. Gelatin
zymography was performed on 84 human breast carcinomas and seven normal breast tissues. The precursor form of MMP-2 (72 kDa) was
found in 11 (12%) samples, while its two activated forms, i.e. 62 kDa and 59 kDa, were found in three (6%) and 34 (40%) samples
respectively. In contrast to MMP-2, most ofthe samples (52%) contained MMP-9 in its precursorform. Using ELISA, MMP-1 levels were found
in 12% of the samples while MMP-3 levels were found in only 2% of the samples. Levels of MMP-2, -3 and -9 correlated inversely with
numbers of nodal metastases. Neither MMP-2 nor -9 levels were significantly related to patient outcome. However, patients with high levels
of a 50-kDa gelatinase band after zymography had a significantly better survival than patients with low levels. This species was never
observed in normal breast tissue.
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The escape of breast cancer cells into neighbouring tissues can
lead to the formation of distant metastasis, the most insidious
aspect of cancer. It is generally believed that one key element of
this metastatic process is the enhanced proteolysis of both base-
ment membrane and stromal extracellular matrix (ECM). Among
the proteinases capable of degrading these barriers are the matrix
metalloproteinases (MMPs), a family ofhighly homologous zinc-
dependent endopeptidases (Matrisian, 1990).
Based on the protein domain structure, the MMPs can be
divided into five main groups (MacDougall and Matrisian, 1995).
MMP-7 or matrilysin contains the minimal number of domains,
i.e., a predomain, a prodomain and a catalytic domain. MMP-3
(stromelysin-1), MMP-10 (stromelysin-2), MMP-1 1 (stromelysin-
3) and MMP-12 (metalloelastase) contain an additional carboxy-
terminal haemopexin-like domain and represent the second group.
The stromelysins have a broad substrate specificity and are
capable ofdegrading many extracellular components, e.g. laminin,
fibronectin and proteoglycans. The third group is composed of
MMP-1 (interstitial collagenase), MMP-8 (neutrophil collagenase)
and MMP-13 (collagenase 3). These MMPs degrade fibrillarcolla-
gens and all members of this group have a distinct size and
sequence composition in their hinge domain. The most recently
described group ofMMPs are the membrane-type matrix metallo-
proteinases. At least some members ofthis group play a role in the
activation ofMMP-2 (Sato et al, 1994; Takino et al, 1995). MMP-
2 (gelatinase A) and MMP-9 (gelatinase B) account for a separate
class based on the presence of a fibronectin-like domain.
Gelatinases are able to cleave both the denatured forms ofcollagen
and type IV collagen found in basement membranes. In addition to
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the fibronectin-like domain, MMP-2 and -9 contain a gelatin-
binding domain that endows them with high affinity for gelatin.
This property is used in the concentration or in the purification of
these enzymes by affinity chromatography on gelatin-Sepharose
beads (Chen et al, 1991; Remacle et al, 1995).
The MMPs are all produced as latent proenzymes which
undergo proteolytic cleavage of an amino terminal domain during
activation (Atkinson et al, 1992; Kleiner and Stetler-Stevenson,
1993). The net activity of MMPs is determined by the amount of
proenzyme expressed, the extent to which the proenzyme is acti-
vated and the local concentration of specific tissue inhibitors of
MMPs, i.e. the TIMPs. Fourdifferent TIMPS have been identified:
TIMP-1, TIMP-2, TIMP-3 and TIMP-4 (DeClerck et al, 1989;
Leco et al, 1994; Apte et al, 1995; Green et al, 1996). TIMP-1 and
TIMP-2 have molecular weights of 28.5 and 21 kDa respectively,
and appearto actby forming 1:1 stoichiometric complexes withthe
active MMP. However, TIMP-1 also binds to the precursor form of
MMP-9, while TIMP-2 binds to the precursor form of MMP-2
(Wilhelm et al, 1989), suggesting that they may selectively modu-
late activity ofthese enzymes (Fridman et al, 1992).
Considerable evidence from model systems suggests that certain
MMPs play a role in cancer invasion and metastasis (Alvarez et al,
1990; Hoyhtya et al, 1990; DeClerck et al, 1992; Duffy, 1992;
Aznavooran et al, 1993). Consistent with their role in experimental
metastasis, gelatinases, in particular, have been found to be
elevated in many human cancers such as breast (Monteagudo et al,
1990; Davies et al, 1993), colon (D'Errico et al, 1991), prostate
(Stearns and Wang, 1993) and ovarian (Autio-Harmainen et al,
1993). Tumour cells may either secrete these enzymes themselves
or induce the host cells within the tumour stroma to produce them
(Noel et al, 1994; Ito et al, 1995).
The aim of this investigation was to measure different MMPs in
extracts ofboth normal breast tissue and primary breast cancers. In
the breast cancers, we related levels ofthe different MMPs to patho-
logical characteristics ofthe tumour and to patient outcome. Gelatin
zymography was used to resolve the activated species from the
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Table 1 Clinicopathological parameters of the 84 primary breast cancers
Patients
Number %
Nodal status
Positive
Negative
Unknown
Tumour size
0-2 cm
2-5 cm
> 5 cm
Unknown
ERa
Positive
Negative
Unknown
PRb
Positive
Negative
Unknown
38
29
17
31
37
6
10
63
19
2
37
40
7
45.2
34.5
20.3
36.9
44.1
7.1
11.9
75.0
22.6
2.4
44.0
47.6
8.4
aOestrogen receptor. bProgesterone receptor.
latentproenzyme ofgelatinases (MMP-2 and -9). We alsoquantified
the MMP-l (interstitial collagenase) and MMP-3 (stromelysin-1)
using an enzyme-linked immunosorbent assay (ELISA).
MATERIALS AND METHODS
Tumours and patients
Normal breast tissue collected during reduction mammoplasty and
primary breast tumours were homogenized in 50 mM Tris-HCl
buffer pH 7.4 containing 1 mM monothiolglycerol. Homogenates
were centrifuged at 2000g for Omin and supernatants were
A 1 2 3
Mr 92 000 -
Mr 62000 _
Mr59 000
Mr45 000 -
stored at -75°C until assayed. Protein concentrations of the
extracts were determined using the Bio-Rad protein assay. The
oestrogen receptor (ER) and progesterone receptor (PR) content of
the primary breast tumours were measured using ELISA as previ-
ously described by Duffy et al (1986). Details ofthe axillary node
status, tumour size, ER and PR levels of the 84 patients on whom
the MMP assays were prepared are summarized in Table 1. Of
these 84 patients, follow-up data were available on 80. Median
patient follow-up was 25 months.
Gelatin zymography
Gelatin zymography was performed as previously described
(Heussen and Dowdle, 1980; Remacle et al, 1995). Forty micro-
grams of total protein was mixed with non-reducing electro-
phoresis buffer. Electrophoresis was carried out on a 10%
polyacrylamide gel containing gelatin at a final concentration of
1 mg ml-'. Gelatinase activity was detected as clear zones of lysis
against a blue background. The amount of each gelatinolytic
activity band was measured by determining the area ofthe cleared
band. The degree of digestion was quantified using a Model GS-
700 Imaging Densitometer (Bio-Rad, Richmond, CA, USA)
equipped with Molecular Analyst software. Each gel was scanned
three times and the average value of the integrated density for a
particular band was used for further calculations. Results were
expressed in arbitrary units per 40 jig of total protein. We verified
that addition of protease inhibitors (1 mM phenylmethane
sulphonyl, fluoride 1 mM N-ethylmaleimide, 1 jg ml-' Pepstatin
A) did not modify either the activation rate ofgelatinases nor their
degradation.
Medium conditioned by subconfluent human fibrosarcoma
HT1080 cells treated with 12-O-tetradecanoylphorbol-13-acetate
(TPA) (10 ng ml-') for 48 h, was used as gelatinase standards as
previously described (Brown et al, 1993; Davies et al, 1993;
Liabakk et al, 1996). The identities of the gelatinase species in
this medium have been previously determined by Western blot
analysis (Brown et al, 1990, 1993).
C
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Figure 1 Gelatinolytic activity in normal human (A) and malignant (B) breast tissue extracts. Samples of breast tissue were extracted and processed for
gelatin zymography as described in Materials and methods. Lane 1, 7gl of culture medium conditioned by 48-h TPA treated HT-1080 cells, containing the latent
92-kDa progelatinase B, the latent 72-kDa progelatinase A and its two activated forms with 62 kDa and 59 kDa; lanes 2-8, seven representative samples of
normal (A) or malignant (B) breast tissue extracts illustrating the typical patterns of gelatinolytic activity. Gels containing tumour extracts were incubated in the
absence (B) or in the presence (C) of 20 mm EDTA to confirm that the bands contained MMP-like activities
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ELISA
MMP-1 and MMP-3 levels were assayed by ELISA using kits
obtained from Fuji Chemical Industries (Takaoda, Toyama 933,
Japan). According to the supplier, the MMP-l assay primarily
detects the proform. However, it also detects the active form, MMP-
I/TIMP-1 complex and MMP-1/TIMP-2 complex with an effi-
ciency ofapproximately 50%, 10% and less than 3% respectively.
The MMP-3 ELISA also detects the pro- and active forms as
well as MMP-3/TIMP complexes. However, the relative efficiency
in detecting these different forms of MMP-3 was not stated in the
kit insert. An arbitrary cut-off point of 1 ng mg-' protein and
5 ng mg-' protein was used for MMP-1 and MMP-3 respectively.
For standardization, we used purified precursor forms ofhuman
MMP-1 and MMP-3 provided in the ELISA kits.
Statistical analysis
Levels ofthe different MMPs were related to both one another and
to established prognostic markers for breast cancer using the
Spearman-coefficient of rank correlation. Differences in patient
outcome between groups were determined using the log-rank test.
RESULTS
MMPs with gelatinolytic activities in normal breast
samples
We have performed gelatin zymography on normal breast tissue.
The gelatinolytic pattern of the seven samples analysed was
constant anddisplayed seven different bands of 116, 92, 84,77,72,
62 and 45 kDa (Figure IA). A 150-kDa species was detected in
only one sample. Gelatinase A was detected in its proform
(72 kDa) and intermediate active form (62 kDa). However, its fully
active 59-kDa form was never observed.
Levels of the different MMPs in breast cancers
The proportion of breast cancers positive for the different MMPs is
shown in Table 2. After gelatin zymography a total of 11 different
bands were seen with molecular weights ranging from 36.5 to
150 kDa. However, as shown in Figure iB, both the number and
intensity of bands varied from sample to sample. Inhibition with
Table 2 Percentage positive, mean values and range of values for different
MMPs in primary breast cancers
MMPs Positive samples Mean Range of
values
n %
150 kDa 15 18 9.00 0-537
100 kDa 11 13 8.10 0-387
92 kDa 44 52 19.90 0-486
84 kDa 8 10 4.00 0-140
75 kDa 7 8 0.90 0-44
72 kDa 11 12 11.50 0-346
62kDa 3 6 0.80 0-52
59 kDa 34 40 21.50 0-254
54.5 kDa 18 21 13.50 0-221
50 kDa 44 52 38.20 0-407
36.5 kDa 3 4 0.30 0-23
MMP-1 10 12 0.283 0-4.3
MMP-3 2 2 0.338 0-7.5
For those MMPs measured by zymography, levels are given in arbitrary units
and for the MMP-1 and MMP-3 detected by ELISAs, values are ng mg-'
protein.
20 mi EDTA (Figure IC) or with 1 mi phenanthroline (data not
shown) indicated the metalloproteinase nature of these gelatinase
bands.
Three different forms of gelatinase A (MMP-2) were detected,
i.e. the 72-kDa progelatinase A and its two activated forms,
migrating as 62- and 59-kDa proteins. While the precursor form
was found in only 12% of samples, the 62-kDa band was found in
6% and the 59-kDa band in 40%. The 59-kDa activated form of
gelatinase A was observed in 10 of 11 (91%) tumours positive for
the 72-kDa species, and in 24 of 73 (33%) samples lacking this
band (P = 0.0022). Furthermore, as shown in Table 2, the mean
activity ofthe 59-kDa activated form was approximatively twice as
high as that of the progelatinase 72-kDa form. These results
demonstrate that in most of the tumour samples gelatinase A is
detected in its 59-kDa activated form.
The precursor form ofgelatinase B (92-kDa band) was found in
52% of the samples, while its activated form (84-kDa band) was
present in only 10%. The 84-kDa activatedform ofgelatinase B was
detectedinS outof44 (11%) tumoursamplescontainingthe 92-kDa
proenzyme andin 3 of40(7%) samples withoutthis species (P= not
Table 3 Relationship between the different MMPs in primary breast cancers
150 kDa -
100 kDa 0.436
92 kDa 0.502 NS
84kDa 0.283 0.378 NS -
75 kDa 0.346 NS 0.299 0.508 -
72 kDa 0.441 NS 0.417 0.424 0.726 -
62 kDa 0.449 NS 0.326 0.615 0.660 0.517
59 kDa 0.353 NS 0.499 0.236 0.247* 0.386 0.386
54.5 kDa NS 0.221* NS 0.321 NS NS NS NS
50 kDa NS NS 0.318 NS NS NS NS 0.656 NS
36.5 kDa NS 0.489 NS NS NS NS NS NS NS NS
MMP-1 0.345 NS NS NS 0.269* 0.313 0.249* NS -0.238* NS NS -
MMP-3 NS NS NS NS NS NS NS NS NS NS NS NS -
150 kDa 100 kDa 92 kDa 84 kDa 75 kDa 72 kDa 62 kDa 59 kDa 54.5 kDa 50 kDa 36.5 kDa MMP-1 MMP-3
The values quoted are r-values (Spearman rank coefficient of correlation). P < 0.005, except when indicated by *, when P< 0.005. NS, not significant.
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Figure 2 Gelatin zymography of human breast cancer extracts treated with
gelatin-Sepharose beads. Lane 1, 7 gI of culture medium conditioned by
48-h TPA-treated HT-1080 cells, used as gelatinase A and markers; lane 2,
a pool of several breast cancertissue extracts (= sample P) containing the
50-kDa gelatinolytic activity band before gelatin-Sepharose beads; lane 3,
unbound fraction of sample P to gelatin-Sepharose beads; lane 4, bound
fraction of sample P, eluted from gelatin-Sepharose beads. The 50-kDa band
is indicated by an arrow
Table 4 Relationship between MMP levels and the number of axillary node
metastases
MMPs r P
MMP-3 (Total) -0.238 0.0300
MMP-2 (Pro) -0.350 0.0410
MMP-2 (Activea) -0.284 0.0199
MMP-9 (Pro) -0.306 0.0120
a59-kDa form.
(it
2
0
a
.3
E._
c)
0
0~
2
a.
1'
0.9
0.8-
0.7-
0.6-
0.5-
0.4-
0.3
0.2-
0.1
- 50 kDa Undetectable (n = 38)
--50 kDa Present (n = 42)
6 i 5 4
Time (years)
Figure 3 Relationship between the 50-kDa gelatinase activity levels and
overall survival in patients with breast cancer. The cut-off point used was
detectable levels of the 50-kDa band. Median follow-up was 25 months
(P = 0.0014, log rank chi-square 10.2)
significant). These results suggest that gelatinase B was mainly
expressed as its 92-kDa zymogen form. Furthermore, the mean
activity ofthe 84-kDa activated gelatinase B form detected in some
primary tumours was about five times lower than that ofthe proge-
latinase B (Table 2). Theproportion ofsamples positive forthe other
gelatinases is summarized in Table 2. Itis interesting to note that the
50-kDa species observed in 52% of tumour extracts was never
observed in normal breast tissue (Figure 1A).
MMP-1 immunoreactivity levels (greater than 1 ng mg-'
protein) were found in 12% of samples while MMP-3 immuno-
reactivity (greater than 5 ng mg-' protein) was detected in only
2%. Mean levels of MMP-l were 0.283 ng mg-1 protein (range
0-4.30 ng mg-' protein), while mean levels of MMP-3 were
0.338 ng mg-' protein (range 0-7.50 ng mg-' protein).
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Relationship between the different MMPs
Table 3 summarizes the relationship between the different MMPs.
Ofnote is the significant butweak relationship between gelatinase B
and both the precursor and active forms ofgelatinase A. In contrast,
gelatinase B activity did not correlate with either MMP- or MMP-
3 levels. However, MMP-1 but not MMP-3 levels correlated with
both the precursor and the 62-kDa active form ofgelatinase A.
Relationship between different MMPs and
clinicopathological parameters
None ofthe well-characterized metalloproteinases, such as MMP-
1, -3, gelatinase A or B, correlated significantly with tumour size.
However, levels of the 50-kDa band showed a weak, but statisti-
cally significant, inverse relationship with size (r = -0.245, P =
0.0442). The nature of this 50-kDa band has not yet been identi-
fied. In an attempt to characterize this species, different cancer
extracts containing this 50-kDa form were pooled and incubated
with gelatin-Sepharose beads before analysis by gelatin zymog-
raphy. The 50-kDa gelatinolytic band was recovered in the
unbound fraction (Figure 2). These results indicated that the
50-kDa species did not contain the gelatin-binding domain
characteristic of gelatinases A and B and furthermore that it could
not be a degradation product ofthese enzymes.
In contrast to the lack of correlation with tumour size, certain
MMPs correlated inversely with nodal status (Table 4). There was
no significant relationship between high levels ofMMP-2 or -9 and
patient outcome. Because ofthe low proportion oftumours positive
for both MMP-1 (12%) and MMP-3 (2%), it was not possible to
reliably relate levels ofthese MMPs to patient outcome. However,
as shown in Figure 3, patients with a high level of the 50-kDa
species had a significantly better survival than patients with low
levels of this form (P = 0.0014). The relationship between the
50-kDa band and disease-free interval was not significant.
DISCUSSION
This study describes the distribution of multiple MMPs in normal
and malignant breast tissues. Using ELISA, we show that MMP-1
and MMP-3 are detectable in only a minority ofbreast cancers. To
our knowledge, neither MMP-1 nor -3 protein levels have previ-
ously been assayed by a quantitative assay in breast cancer. Using
in situ hybridization, Polette et al (1993) found expression ofboth
MMP-l and -3 in 2 out of 17 breast carcinomas, while Heppner et
al (1996) found expression ofboth proteinases in 3 out of 11 inva-
sive breast cancers. Ourresults using ELISA are thus in agreement
with the finding using in situ hybridization, with both approaches
suggesting that both MMP-1 and -3 are only expressed by a small
proportion ofhuman breast cancers.
Using gelatin zymography we found 11 different bands in
tumour extracts. MMP-9 (gelatinase B) was mainly detected as a
zymogen (92 kDa) and not as an active enzyme (84 kDa). On the
contrary, gelatinolytic activity corresponding to one of the two
activated forms of MMP-2 (i.e., the 59-kDa form) were more
frequently observed than the precursor form and were more
intense than that corresponding to progelatinase A (72 kDa). On
the contrary, this fully active form of gelatinase A was never
observed in the normal breast samples analysed. Our findings are
in agreement with other studies suggesting that the activation of
MMP-2 (gelatinase A) is a more common event in human breast
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carcinoma than the activation of MMP-9 (gelatinase B) (Brown et
al, 1993; Davies et al, 1993). The proportion ofsamples containing
progelatinase B in the present investigation, i.e. 52%, was very
similar to that previously described (Brown et al, 1993; Davies et
al, 1993). However, in contrast to previous reports (Brown et al,
1993; Davies et al, 1993; Sik Lee et al, 1996), we found progelati-
nase A in only a minority of samples. In the present study, as
mentioned above, most of this MMP was detected in its activated
59-kDa form. These different findings on the proportion of
samples positive for progelatinase A may relate to factors such as
composition of homogenization buffers, handling and storage of
tumours and/or cell-free extracts.
Previously, using ELISA, we showed a significant correlation
between levels of MMP-8 and -9 in breast cancer (Duffy et al,
1995). In the present investigation, we show a significant associa-
tion between MMP-9 activity and MMP-2 activity (both precursor
and active forms). However, MMP-9 activity showed no signifi-
cant relation with either levels of MMP-1 or MMP-3. These find-
ings suggest that similar factors may be controlling the levels of
different MMPs in breast cancer. In this investigation, no signifi-
cant association was found between levels of the established
MMPs and tumour size. Using a smaller number of samples (i.e.
20), Brown et al (1993) also found no relationship between activity
levels ofeither MMP-2 or -9 and tumour size. However, in contrast
to Brown et al (1993), we found a weak but significant inverse
relationship between axillary node metastases and levels ofMMP-
2,-3 and-9.
Previously, high levels of a number ofdifferent proteases impli-
cated in metastasis, such as urokinase plasminogen activator,
cathepsin B and cathepsin D have been found to predict poor prog-
nosis in patients with breast cancer (for review, see Duffy, 1992).
In this preliminary study of 84 patients with a median follow-up
time of 25 months, no significant relationship was found between
levels ofeither MMP-1, -2, -3 or-9 and patient outcome. Similarly,
using immunohistochemistry, Visscher et al (1994) found no rela-
tionship between levels ofeither MMP-2 or MMP-9 and prognosis
in breast cancer, while Daidone et al (1991) found no association
between 'collagenase IV' levels and either relapse-free survival or
overall survival in axillary node-negative breast cancer patients.
Unlike the MMPs investigated in the present study, we have
recently shown that levels of at least one MMP, i.e. stromelysin-3,
correlates with outcome in breast cancer patients (Chenard et al,
1996). It is also worth noting that while MMP-2 and -9 do not
appear to be associated with prognosis in breast cancer, they are
predictive of outcome on at least one type of cancer, i.e. gastric
carcinoma (Sier et al, 1996). More sensitive assays are required to
address the relationship between levels ofboth MMP-1 and -3, and
tumour aggressiveness.
While levels ofMMP-1, -2, -3 and -9 were not related to patient
outcome in the present study, high levels of a previously
unreported gelatinase, i.e. a 50-kDa band, were associated with
improved overall survival. This 50-kDa species was never
observed in normal breast extracts analysed. Although the identity
of the 50-kDa band is unknown, our data suggests that it is unre-
lated to interstitial collagenase or to stromelysin-1, which exhibit
similar molecular weight, but which display only weak gelatinase
activity (Brown et al, 1990). Furthermore, the lack of binding of
this 50-kDa form to gelatin-Sepharose beads suggests that this
enzymatic species could notbe adegradation product ofthe known
gelatinases. Indeed, gelatinase A and B are both characterized by a
gelatin binding site in their catalytic domain (Matrisian, 1990;
Kleiner and Stetler-Stevenson, 1993). This domain to be appears to
be implicated in the gelatinolytic activity, as a mutant ofgelatinase
A from which this domain has been deleted retained only 10% of
its activity against gelatin (Murphy et al, 1994).
The lack of correlation between levels of MMP-2 and -9 and
patient prognosis observed in this study does not necessarily mean
that these proteinases are not involved in the metastasis of breast
cancer. It should be borne in mind that this is a preliminary study
with only 80 patients having follow-up and the median follow-up
being only 25 months. Furthermore, no attempt was made in the
present study to establish the optimum conditions for extracting
the different MMPs. Finally, the ratio of MMPs to TIMPs may be
more important in determining clinical outcome than levels of
MMPs alone. Further studies are thus clearly necessary to estab-
lish whether MMP-1, -2, -3 or -9 are related to patient prognosis.
Irrespective of whether or not the above MMPs are related to
clinical outcome, their measurement in primary cancers might be
useful in predicting responses to MMP inhibitors. Inhibitors of
MMPs have been shown to prevent or decrease the formation of
metastases in animal model systems (Brown and Giavazzi, 1995).
Furthermore, in recent years, certain MMP inhibitors have entered
clinical trials. A goal to the future should be to see whether any
relationship exists between the levels and the profile ofMMPs in a
cancer and response to this new form ofcancer therapy.
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